Cytomx Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the 2017 Annual Meeting of Stockholders held by Cytomx Therapeutics, Inc. on June 20, 2017. The report details the voting results for two proposals submitted to security holders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance report regarding stockholder voting and does not contain financial performance data.
Material Changes
No material financial changes are reported in this filing. The document reports on the outcome of the Annual Meeting, specifically the election of directors and the ratification of the independent auditor.
Guidance, Outlook, and Management Commentary
The filing contains no guidance, outlook, or management commentary regarding future financial performance. It strictly reports the results of the stockholder vote.
Important Facts for Investors
- Shareholder Participation: As of the April 28, 2017 record date, 36,743,701 shares were outstanding. A total of 28,934,990 shares were voted at the meeting.
- Director Elections (Proposal 1): Stockholders elected three Class II director nominees to serve until the 2020 Annual Meeting:
- Neil Exter: 24,473,817 votes For.
- Frederick W. Gluck: 24,485,859 votes For.
- Matthew P. Young: 23,835,087 votes For.
- Auditor Ratification (Proposal 2): Stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2017, with 28,924,579 votes For.
- Broker Non-Votes: There were 3,820,189 broker non-votes recorded for the director elections, which did not affect the outcome as the proposals required a plurality of votes cast.